Catalyst Wire Dossier Catalyst Wire Dossier

recombinant Factor XIII replacement therapy

Factor XIII · Novo Nordisk A/S
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for recombinant Factor XIII replacement therapy, covering 2016-12-13 to 2016-12-13. Get the full timeline:

Most recent: Clinical Trial Update: Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 [Phase 3]

See pricing